94 results
Page 2 of 5
8-K
EX-99.1
sy1u8qs
14 Jun 23
NanoVibronix Announces Distribution Agreement with Sports Medicine Supplier Mio-Guard
8:30am
DEFA14A
EX-99.1
bcn73
18 May 23
Additional proxy soliciting materials
8:32am
8-K
EX-99.1
med4e6zqt6221x 2o
18 May 23
NanoVibronix Issues Letter to Shareholders
8:30am
8-K
EX-99.1
gbxejj 0f5k3m2vbf
15 Dec 22
Nanovibronix Announces Results of Annual Meeting of Stockholders Held Today
5:29pm
8-K
EX-99.1
bibra j96m
1 Dec 22
NanoVibronix Announces $2.4 Million Registered
6:06am
424B5
ct4pch7znxb7 u2e
30 Nov 22
Prospectus supplement for primary offering
5:29pm
8-K
EX-99.1
oqp akpl3y8j9yoa
29 Nov 22
NanoVibronix Receives FDA 510(k) Premarket Clearance for PainShield Plus
9:13am
8-K
EX-99.1
d68k7
16 Nov 22
NanoVibronix Announces Interim Results of Clinical Study for UroShield
8:30am
DEFA14A
glbw24g
15 Nov 22
Additional proxy soliciting materials
9:26am
8-K
EX-99.1
kwi3u56t8uguz79y1i
19 Oct 22
NanoVibronix Receives Extension to Satisfy Nasdaq Price Requirement
8:30am
8-K
EX-99.1
jzul zwrun
23 Sep 22
NanoVibronix UroShield Approved for Sale through NHS Internal
8:30am
DEFA14A
tc6q5p1dq 45stv
15 Sep 22
Additional proxy soliciting materials
9:40am
8-K
EX-99.1
df4iikee
15 Sep 22
Nanovibronix Sets Date for Annual Shareholder Meeting
9:30am
8-K
EX-99.1
lg113
14 Sep 22
NanoVibronix Announces Distribution of Series F Preferred Stock to Holders of its Common Stock
10:21am
8-K
EX-99.1
69ogne35
2 Sep 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:30pm
8-K
EX-99.1
2j5j4kvuv0
17 May 22
Nanovibronix Reports First Quarter 2022 Financial Results
8:30am
8-K
EX-99.1
nzv2347vgxmdam4 c2
14 Jan 22
NanoVibronix Expands Board of Directors with Appointment of Two New
11:19am
8-K
EX-99.1
xk4o88qhv
12 Oct 21
Nanovibronix Announces Positive Results from
9:00am